My Cart

Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (MALS & SPR verified)

Customer Reviews
Cat. No. / Size
Price
Qty
HL1-H52E7-25ug
$290.00
HL1-H52E7-200ug
$1815.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

  • Synonym

    HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV)

  • Source

    Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (HL1-H52E7) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQV peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & SLLMWITQV).

    Predicted N-terminus: Gly 25 & Ser

  • Molecular Characterization

    Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein is assembled by biotinylated monomer (HL1-H82E4) and streptavidin.

    Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide. Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 36.3 kDa, 13.8 kDa and 13.3 kDa. The protein migrates as 42-45 kDa, 15 kDa and 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV) SDS-PAGE

    Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • SEC-MALS

    HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV) SEC-MALS

    The purity of Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-H52E7) is more than 95% and the molecular weight of this protein is around 290-320 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV) ELISA

    Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-H52E7) at 5 μg/mL (100 μL/well) can bind Anti-NY-ESO-1 Antibody, Human IgG1 with a linear range of 0.3-5 ng/mL (QC tested).

    Protocol
  •  HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV) ELISA

    Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-H52E7) at 1 μg/mL (100 μL/well) can bind Anti-B2M Antibody, Human IgG1 with a linear range of 0.1-1 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV) SPR

    Anti-NY-ESO-1 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-H52E7) with an affinity constant of 1.15 nM as determined in a SPR assay (Biacore 8K) (QC tested).

    Protocol
  •  HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV) SPR

    Human NY-ESO-1 TCR Protein, Fc Tag captured on Protein A Chip can bind Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-H52E7) with an affinity constant of 15.7 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 (SLLMWITQV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland